The Role of Plasma as a Potential Alternative to EGFR Mutation Analysis in NSCLC

August 4, 2016
Nicola Normanno, MD

Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the recent data showing that plasma can act as a potential alternative to EGFR mutation analysis in the treatment of patients with non-small cell lung cancer, as well as the current demands for the use of liquid biopsies in this type of treatment.